NCT06557304尚未招募不适用
This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,000
- 主要终点
- Overall Survival
研究概览
简要总结
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥18 years old
- •Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
- •Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
- •Prior or current use of BTK inhibitor for ≥3 months
- •At least one follow-up was recorded during BTK inhibitor treatment
排除标准
- 未提供
结局指标
主要结局
Overall Survival
时间窗: up to five years
OS is defined as the time from the starting date of BTK inhibitor to the date of death due to any cause.
次要结局
- Time to Next Therapy (TTNT)(up to two years)
- Adverse Events(up to five years)
研究者
Xiao-Jun Huang
Prof.
Peking University People's Hospital
相似试验
尚未招募
不适用
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in ChinaCLLNCT06489184Peking University People's Hospital490
尚未招募
不适用
the Real World Study of Orelabrutinib in the Treatment of CLL/SLLCLL/SLLNCT05975164Shandong University50
尚未招募
2 期
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaLymphoma, Mantle-CellLymphoma, Non-HodgkinNCT06427213Henan Cancer Hospital41
进行中（未招募）
3 期
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibB-cell MalignanciesNCT04170283BeOne Medicines955
招募中
不适用
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABCHER2-positive Breast CancerNCT06754059zhangjie60